<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02820597</url>
  </required_header>
  <id_info>
    <org_study_id>A2014-02</org_study_id>
    <nct_id>NCT02820597</nct_id>
  </id_info>
  <brief_title>ClariFix Cryoablation Clinical Study</brief_title>
  <official_title>Clinical Evaluation of Cryotherapy in the Nasal Passageway Using the ClariFix Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arrinex, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arrinex, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-arm pilot study designed to evaluate the feasibility of cryoablation in the
      nasal passageway, using the ClariFix device, to reduce the symptoms of chronic rhinitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a small, prospective, multicenter, single-arm, self-controlled interventional
      feasibility study to evaluation cryoablation in the nasal passage as a treatment for chronic
      rhinitis. The ClariFix device is FDA-cleared device with the intended use for the destruction
      of unwanted tissue during surgical procedures, including in adults with chronic rhinitis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 15, 2015</start_date>
  <completion_date type="Actual">July 20, 2016</completion_date>
  <primary_completion_date type="Actual">February 5, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Device- and/or Procedure-related Serious Adverse Events</measure>
    <time_frame>Baseline through 365 days post treatment</time_frame>
    <description>Number of participants with device- and/or procedure-related serious adverse events reported over the initial study follow-up period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Rhinitis Symptom Severity (rTNSS)</measure>
    <time_frame>Baseline through 365 days post treatment</time_frame>
    <description>Change from baseline in participant-reported symptom severity based on the rTNSS (Reflective Total Nasal Symptom Score). The rTNSS is the sum of 4 individual subject-assessed symptom scores for rhinorrhea, nasal congestion, nasal itching, and sneezing, each evaluated using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe. The rTNSS has a possible score range of 0-12. The reflective scores are based on the participant's evaluation of symptom severity over the preceding 12 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Rhinitis Symptoms (VAS)</measure>
    <time_frame>Baseline through 365 days post treatment</time_frame>
    <description>Change from baseline in rhinitis symptoms measured on a participant-reported visual analog scale (VAS). Symptoms of rhinorrhea, nasal breathing, facial pain/pressure, and sense of smell were rated from 0 (no symptoms) to 10 (severe/extremely bothersome symptoms) assessed over the 12 hours preceding the visit. An average of the 4 individual scores was used as the total VAS score with a range of 0 to 10.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ease of Use</measure>
    <time_frame>Immediately post treatment</time_frame>
    <description>Physician evaluation of ClariFix ease of use. After each participant's treatment, the physician was asked to rate the ClariFix on ease of use. Options were easy, moderately easy, moderately difficult, or difficult.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device- and/or Procedure-related Adverse Events</measure>
    <time_frame>Baseline through 90 days post treatment</time_frame>
    <description>All adverse events evaluated as possibly, probably, or definitely related to the ClariFix device and/or procedure.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Rhinitis</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cryoablation with the ClariFix device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ClariFix device</intervention_name>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is &gt;21 years of age

          2. Subject has had moderate to severe symptoms of rhinorrhea and/or nasal congestion for
             &gt;3 months (rTNSS rating of 2 or 3)

          3. Subject has signed IRB-approved informed consent form

        Exclusion Criteria:

          1. Subject has clinically significant anatomic obstructions that limit access to the
             posterior nose including severe septal deviation, nasal polyps, and sinonasal tumor

          2. Subject has a septal perforation

          3. Subject has had prior sinus or nasal surgery that significantly alters the anatomy of
             the posterior nose

          4. Subject has had prior head or neck irradiation

          5. Subject has active or chronic nasal or sinus infection

          6. Subject has active coagulation disorder or patient is receiving anti-coagulants which
             cannot be safely stopped for 2 weeks

          7. Subject has a history of dry nose symptoms

          8. Subject is pregnant or lactating

          9. Subject is participating in another clinical research study

         10. Subject has an allergy or intolerance to anesthetic agent

         11. Subject is an active smoker or has been a smoker within the last 6 months

         12. Any physical condition that in the investigator's opinion would prevent adequate study
             participation or pose increased risk
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacob Johnson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>San Francisco Otolaryngology Medical Group</affiliation>
  </overall_official>
  <results_reference>
    <citation>Hwang PH, Lin B, Weiss R, Atkins J, Johnson J. Cryosurgical posterior nasal tissue ablation for the treatment of rhinitis. Int Forum Allergy Rhinol. 2017 Oct;7(10):952-956. doi: 10.1002/alr.21991. Epub 2017 Aug 11.</citation>
    <PMID>28799727</PMID>
  </results_reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>June 29, 2016</study_first_submitted>
  <study_first_submitted_qc>June 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2016</study_first_posted>
  <results_first_submitted>December 10, 2018</results_first_submitted>
  <results_first_submitted_qc>October 17, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 21, 2019</results_first_posted>
  <last_update_submitted>October 17, 2019</last_update_submitted>
  <last_update_submitted_qc>October 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>27 participants were enrolled and treated with bilateral cryotherapy of the nasal passage (54 treatments).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Intervention</title>
          <description>Cryoablation with the ClariFix device</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>1-day Post Treatment</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>7-day Post Treatment</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>30-day Post Treatment</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>90-day Post Treatment</title>
              <participants_list>
                <participants group_id="P1" count="24">2 participants missed the 90-day visit, 1 participant was lost to follow-up.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>180-day Post Treatment</title>
              <participants_list>
                <participants group_id="P1" count="21">3 participants missed the 180-day visit, 3 participants were lost to follow-up.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15">12 participants were lost to follow-up.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intervention</title>
          <description>Treatment with the ClariFix Device
ClariFix Device</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.29" lower_limit="27" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Device- and/or Procedure-related Serious Adverse Events</title>
        <description>Number of participants with device- and/or procedure-related serious adverse events reported over the initial study follow-up period.</description>
        <time_frame>Baseline through 365 days post treatment</time_frame>
        <population>A total of 27 subjects were enrolled and received bilateral cryosurgery with the ClariFix device (n=54 treatments).</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Cryoablation with the ClariFix device</description>
          </group>
        </group_list>
        <measure>
          <title>Device- and/or Procedure-related Serious Adverse Events</title>
          <description>Number of participants with device- and/or procedure-related serious adverse events reported over the initial study follow-up period.</description>
          <population>A total of 27 subjects were enrolled and received bilateral cryosurgery with the ClariFix device (n=54 treatments).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Rhinitis Symptom Severity (rTNSS)</title>
        <description>Change from baseline in participant-reported symptom severity based on the rTNSS (Reflective Total Nasal Symptom Score). The rTNSS is the sum of 4 individual subject-assessed symptom scores for rhinorrhea, nasal congestion, nasal itching, and sneezing, each evaluated using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe. The rTNSS has a possible score range of 0-12. The reflective scores are based on the participant's evaluation of symptom severity over the preceding 12 hours.</description>
        <time_frame>Baseline through 365 days post treatment</time_frame>
        <population>All participants with follow-up at the indicated visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Cryoablation with the ClariFix device</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Rhinitis Symptom Severity (rTNSS)</title>
          <description>Change from baseline in participant-reported symptom severity based on the rTNSS (Reflective Total Nasal Symptom Score). The rTNSS is the sum of 4 individual subject-assessed symptom scores for rhinorrhea, nasal congestion, nasal itching, and sneezing, each evaluated using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe. The rTNSS has a possible score range of 0-12. The reflective scores are based on the participant's evaluation of symptom severity over the preceding 12 hours.</description>
          <population>All participants with follow-up at the indicated visits.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 Days post treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Days post treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.6" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>90 Days post treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>180 Days post treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.0" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>365 Days post treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.5" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis is that the within-participant change from baseline in rTNSS is 0.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Paired t-tests on the mean change from baseline. No adjustments were made for multiple comparisons.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Rhinitis Symptoms (VAS)</title>
        <description>Change from baseline in rhinitis symptoms measured on a participant-reported visual analog scale (VAS). Symptoms of rhinorrhea, nasal breathing, facial pain/pressure, and sense of smell were rated from 0 (no symptoms) to 10 (severe/extremely bothersome symptoms) assessed over the 12 hours preceding the visit. An average of the 4 individual scores was used as the total VAS score with a range of 0 to 10.</description>
        <time_frame>Baseline through 365 days post treatment</time_frame>
        <population>All treated participants with follow-up at the indicated visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Cryoablation with the ClariFix device</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Rhinitis Symptoms (VAS)</title>
          <description>Change from baseline in rhinitis symptoms measured on a participant-reported visual analog scale (VAS). Symptoms of rhinorrhea, nasal breathing, facial pain/pressure, and sense of smell were rated from 0 (no symptoms) to 10 (severe/extremely bothersome symptoms) assessed over the 12 hours preceding the visit. An average of the 4 individual scores was used as the total VAS score with a range of 0 to 10.</description>
          <population>All treated participants with follow-up at the indicated visits.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 Days post treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Days post treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.8" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>90 Days post treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.1" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>180 Days post treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>365 Days post treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.6" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis is that the within-participant change from baseline in rhinitis symptoms VAS is 0.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Paired t-tests on the mean change from baseline. No adjustments were made for multiple comparisons.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ease of Use</title>
        <description>Physician evaluation of ClariFix ease of use. After each participant's treatment, the physician was asked to rate the ClariFix on ease of use. Options were easy, moderately easy, moderately difficult, or difficult.</description>
        <time_frame>Immediately post treatment</time_frame>
        <population>Physician evaluation of ease of use after each ClariFix procedure.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Cryoablation with the ClariFix device</description>
          </group>
        </group_list>
        <measure>
          <title>Ease of Use</title>
          <description>Physician evaluation of ClariFix ease of use. After each participant's treatment, the physician was asked to rate the ClariFix on ease of use. Options were easy, moderately easy, moderately difficult, or difficult.</description>
          <population>Physician evaluation of ease of use after each ClariFix procedure.</population>
          <units>Procedures</units>
          <param>Count of Units</param>
          <units_analyzed>Procedures</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Procedures</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Easy</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderately easy</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderately difficult</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Difficult</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Device- and/or Procedure-related Adverse Events</title>
        <description>All adverse events evaluated as possibly, probably, or definitely related to the ClariFix device and/or procedure.</description>
        <time_frame>Baseline through 90 days post treatment</time_frame>
        <population>All treated participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Cryoablation with the ClariFix device</description>
          </group>
        </group_list>
        <measure>
          <title>Device- and/or Procedure-related Adverse Events</title>
          <description>All adverse events evaluated as possibly, probably, or definitely related to the ClariFix device and/or procedure.</description>
          <population>All treated participants.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 Year</time_frame>
      <desc>Adverse events were systematically reported at each follow-up visit.</desc>
      <group_list>
        <group group_id="E1">
          <title>Intervention</title>
          <description>Treatment with the ClariFix Device
ClariFix Device</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Ear blockage</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Nasal Dryness</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Epitaxsis</sub_title>
                <description>Moderate nosebleed</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This is a feasibility study based on a small population of participants.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Principal Clinical Research &amp; Publications Manager</name_or_title>
      <organization>Stryker ENT</organization>
      <phone>763-463-1598</phone>
      <email>ellen.omalley@stryker.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

